bluebird bio, Inc. (NASDAQ:BLUE) Q1 2024 Earnings Call Transcript May 9, 2024
bluebird bio, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).
Operator: Thank you for standing by, and welcome to the bluebird bio First Quarter 202 Results Call. [Operator Instructions] Finally, you are reminded that this conference is being recorded.
I would like to turn the call over to Courtney O’Leary from Investor Relations. Please go ahead.
Courtney O’Leary: Good morning, everyone, and thank you for joining our first quarter 2024 results call today. My name is Courtney O’Leary, Director of Investor Relations at bluebird bio.
Before we begin, let me review our safe harbor statement. Today’s discussion contains statements that are forward-looking under the Private Securities Litigation Reform Act of 1995, including expectations regarding our future financial results and financial position, in addition to statements of the company’s plans, expectations or intentions regarding regulatory progress, commercialization plans and business operations. Such statements are based on current expectations and assumptions that are subject to risks and uncertainties and involve a number of risk factors that could cause actual results to differ materially from projected results.
A description of these risks is contained in our filings with the SEC, which are available on the Investor Relations section of our website, www.bluebirdbio.com.
See also 25 Largest Companies in Mexico by Revenue and 10 Weakest Militaries in Europe.
To continue reading the Q&A session, please click here.